CA1181010A - Pharmaceutical compositions - Google Patents
Pharmaceutical compositionsInfo
- Publication number
- CA1181010A CA1181010A CA000404552A CA404552A CA1181010A CA 1181010 A CA1181010 A CA 1181010A CA 000404552 A CA000404552 A CA 000404552A CA 404552 A CA404552 A CA 404552A CA 1181010 A CA1181010 A CA 1181010A
- Authority
- CA
- Canada
- Prior art keywords
- anagrelide
- amount
- blood platelet
- pharmaceutical composition
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 claims abstract description 84
- 229960001694 anagrelide Drugs 0.000 claims abstract description 83
- 210000001772 blood platelet Anatomy 0.000 claims abstract description 49
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 16
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 claims abstract description 9
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 claims abstract description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 23
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 21
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 18
- 229960001680 ibuprofen Drugs 0.000 claims description 16
- 229960003329 sulfinpyrazone Drugs 0.000 claims description 16
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 claims description 16
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 15
- 229960002009 naproxen Drugs 0.000 claims description 15
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 15
- 239000008203 oral pharmaceutical composition Substances 0.000 claims description 15
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 claims description 15
- 229960003414 zomepirac Drugs 0.000 claims description 14
- 239000002552 dosage form Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 7
- 230000003389 potentiating effect Effects 0.000 claims description 7
- 229960000905 indomethacin Drugs 0.000 claims description 4
- 229960002895 phenylbutazone Drugs 0.000 claims description 4
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000654 additive Substances 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 31
- 208000007536 Thrombosis Diseases 0.000 abstract description 16
- 230000002744 anti-aggregatory effect Effects 0.000 abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000003637 steroidlike Effects 0.000 description 4
- 229940000425 combination drug Drugs 0.000 description 3
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 3
- 229960002768 dipyridamole Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- ULNVBRUIKLYGDF-UHFFFAOYSA-N 1,3-bis(4-methylphenyl)thiourea Chemical compound C1=CC(C)=CC=C1NC(=S)NC1=CC=C(C)C=C1 ULNVBRUIKLYGDF-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LMHIPJMTZHDKEW-XQYLJSSYSA-M Epoprostenol sodium Chemical compound [Na+].O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 LMHIPJMTZHDKEW-XQYLJSSYSA-M 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
- 229960003555 anagrelide hydrochloride Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- -1 sulfinpyra20ne Chemical compound 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLHNUFJSOUSSBA-UHFFFAOYSA-N 1-benzyl-3-(4-propan-2-ylphenyl)thiourea Chemical compound C1=CC(C(C)C)=CC=C1NC(=S)NCC1=CC=CC=C1 XLHNUFJSOUSSBA-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 1
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000005227 alkyl sulfonate group Chemical group 0.000 description 1
- 229940050551 anagrelide 0.5 mg Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- PYRZPBDTPRQYKG-UHFFFAOYSA-N cyclopentene-1-carboxylic acid Chemical compound OC(=O)C1=CCCC1 PYRZPBDTPRQYKG-UHFFFAOYSA-N 0.000 description 1
- 229940075911 depen Drugs 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000003617 indole-3-acetic acid Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004650 metergoline Drugs 0.000 description 1
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- SEEXPXUCHVGZGU-UHFFFAOYSA-M sodium;2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetate Chemical compound [Na+].C1=C(CC([O-])=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C SEEXPXUCHVGZGU-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960003516 zomepirac sodium Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US288,639 | 1981-07-30 | ||
| US06/288,639 US4357330A (en) | 1981-07-30 | 1981-07-30 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1181010A true CA1181010A (en) | 1985-01-15 |
Family
ID=23107996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000404552A Expired CA1181010A (en) | 1981-07-30 | 1982-06-04 | Pharmaceutical compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4357330A (enExample) |
| JP (1) | JPS5826817A (enExample) |
| AU (1) | AU559161B2 (enExample) |
| BE (1) | BE893974A (enExample) |
| CA (1) | CA1181010A (enExample) |
| DE (1) | DE3228402A1 (enExample) |
| FR (1) | FR2510406B1 (enExample) |
| GB (1) | GB2103090B (enExample) |
| IE (1) | IE54277B1 (enExample) |
| LU (1) | LU84306A1 (enExample) |
| MY (1) | MY8800110A (enExample) |
| ZA (1) | ZA825397B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3524051A1 (de) * | 1985-07-05 | 1987-01-15 | Hoechst Ag | Kombinationspraeparate aus hemmstoffen der thrombozytenaggregation und deren verwendung |
| US4837239A (en) * | 1985-08-23 | 1989-06-06 | Syntex (U.S.A.) Inc. | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins |
| EP0270316A3 (en) * | 1986-12-04 | 1989-12-06 | Pfizer Inc. | Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne |
| AT393962B (de) * | 1987-10-22 | 1992-01-10 | Thomae Gmbh Dr K | Synergistische arzneimittelkombination mit einem gehalt an einem phosphodiesterase-hemmer und derenverwendung |
| CA2171073A1 (en) * | 1995-12-04 | 1997-06-05 | Philip C. Lang | Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine |
| EP1216037A2 (en) * | 1999-09-21 | 2002-06-26 | Emory University | Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| US6194420B1 (en) | 1999-11-30 | 2001-02-27 | Roberts Laboratories Inc. | 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof |
| US6388073B1 (en) | 2000-07-26 | 2002-05-14 | Shire Us Inc. | Method for the manufacture of anagrelide |
| EA200801731A1 (ru) * | 2003-01-23 | 2009-10-30 | Шир Холдингз Аг | Составы и способы лечения тробмоцитемии |
| US7700608B2 (en) * | 2004-08-04 | 2010-04-20 | Shire Holdings Ag | Quinazoline derivatives and their use in the treatment of thrombocythemia |
| US20060030574A1 (en) * | 2004-08-04 | 2006-02-09 | Shire Holdings Ag | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors |
| US8304420B2 (en) * | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
| US7910597B2 (en) * | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
| CN101463035A (zh) * | 2007-12-19 | 2009-06-24 | 华生制药私人有限公司 | 生产盐酸阿那格雷一水合物的改进方法 |
| GB2460915B (en) | 2008-06-16 | 2011-05-25 | Biovascular Inc | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| GB201017783D0 (en) | 2010-10-21 | 2010-12-01 | Shire Llc | Process for the preparation of anagrelide and analogues thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2307538A1 (fr) * | 1975-04-18 | 1976-11-12 | Centre Etd Ind Pharma | Nouveau medicament anti-agregant plaquettaire |
| US4124715A (en) | 1977-05-16 | 1978-11-07 | Jose Pozuelo | Method of pharmacologically treating drug addiction with fusaric acid |
-
1981
- 1981-07-30 US US06/288,639 patent/US4357330A/en not_active Expired - Lifetime
-
1982
- 1982-06-04 CA CA000404552A patent/CA1181010A/en not_active Expired
- 1982-07-27 ZA ZA825397A patent/ZA825397B/xx unknown
- 1982-07-28 AU AU86527/82A patent/AU559161B2/en not_active Expired
- 1982-07-29 GB GB08221932A patent/GB2103090B/en not_active Expired
- 1982-07-29 DE DE19823228402 patent/DE3228402A1/de active Granted
- 1982-07-29 BE BE0/208704A patent/BE893974A/fr not_active IP Right Cessation
- 1982-07-29 LU LU84306A patent/LU84306A1/fr unknown
- 1982-07-29 IE IE1828/82A patent/IE54277B1/en not_active IP Right Cessation
- 1982-07-29 FR FR8213262A patent/FR2510406B1/fr not_active Expired
- 1982-07-30 JP JP57132286A patent/JPS5826817A/ja active Granted
-
1988
- 1988-12-30 MY MY110/88A patent/MY8800110A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2510406A1 (fr) | 1983-02-04 |
| DE3228402C2 (enExample) | 1992-01-23 |
| LU84306A1 (fr) | 1983-04-13 |
| FR2510406B1 (fr) | 1986-05-09 |
| GB2103090B (en) | 1985-07-17 |
| AU8652782A (en) | 1983-02-03 |
| ZA825397B (en) | 1983-06-29 |
| IE821828L (en) | 1983-01-30 |
| JPS5826817A (ja) | 1983-02-17 |
| US4357330A (en) | 1982-11-02 |
| DE3228402A1 (de) | 1983-02-24 |
| BE893974A (fr) | 1983-01-31 |
| AU559161B2 (en) | 1987-02-26 |
| GB2103090A (en) | 1983-02-16 |
| JPH0237328B2 (enExample) | 1990-08-23 |
| MY8800110A (en) | 1988-12-31 |
| IE54277B1 (en) | 1989-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4357330A (en) | Pharmaceutical compositions | |
| US5576328A (en) | Method for the secondary prevention of ischemic events | |
| HU199291B (en) | Process for production of synergetic medical compositions containing derivative of xantine and o-acetyl silicium acid | |
| CA2432644C (en) | Pharmaceutical composition comprising aspirintm and cs-747 | |
| US4444777A (en) | Pharmaceutical compositions of anagrelide and sulfinpyrazone | |
| JPS5841821A (ja) | 最少化された胃の損傷を示す抗炎症組成物 | |
| US4694024A (en) | Combination product composed of pyrimido-pyrimidines and O-acetylsalicylic acid or its pharmacologically tolerated salts, and its use | |
| US4432980A (en) | Pharmaceutical compositions | |
| US4576951A (en) | Proglumide, pharmaceutical preparations and compositions including it for use in human pain relief | |
| CS277650B6 (en) | Combination preparation with anti-thrombotic effect | |
| US5260287A (en) | Polyphosphorylated organic compounds: compositions useful in protecting biological tissues | |
| KR20050100676A (ko) | 아세틸살리실산 및 안지오텐신 ⅱ 길항제와 배합된디피리다몰의 뇌졸중 예방을 위한 용도 | |
| HUP0300689A2 (hu) | Eljárás és kompozíciók gyulladásos betegségek kezelésére | |
| JPS6150926B2 (enExample) | ||
| DE3470883D1 (en) | Tetrahydroisoxazolo(4,5-c)pyridine derivatives and preparation thereof | |
| US5665757A (en) | Method for treating anxiety | |
| Riezebos et al. | Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II. Effect on regression of atherosclerosis and restoration of endothelial function | |
| Arruzazabala et al. | D-003 and warfarin interaction on the bleeding time and venous thrombosis experimentally induced in rats | |
| EP0006845A1 (en) | Pharmaceutical composition comprising a 5-aroyl-1-C1-5 alkyl-pyrrole-2-acetic acid compound and acetaminophen or acetylsalicylic acid | |
| Holgate et al. | The bronchoconstrictor activity of adenosine in asthma | |
| Podos | Effect of dipyridamole on prostaglandin-induced ocular hypertension in rabbits. | |
| Kadatz | Inhibition of platelet thrombus formation by pharmacological agents | |
| Peripheral | Tetrachloroethylene. Used in treatment | |
| Nishizawa et al. | An Analog Of Thiazole Which Has Potential Antithrombotic Activity With Low Toxicity | |
| LV14462B (lv) | Kombinēts medicīnisks produkts trombocītu salipšanas kavēšanai |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |